Dipal Doshi - 03 Sep 2024 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Signature
/s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol
TRDA
Transactions as of
03 Sep 2024
Net transactions value
-$136,357
Form type
4
Filing time
05 Sep 2024, 18:49:44 UTC
Previous filing
16 Jul 2024
Next filing
04 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Tax liability $36,692 -2,328 -0.7% $15.76 332,147 03 Sep 2024 Direct F1, F2
transaction TRDA Common Stock Tax liability $12,728 -752 -0.23% $16.93 331,395 03 Sep 2024 Direct F1, F3
transaction TRDA Common Stock Tax liability $1,275 -72 -0.02% $17.70 331,323 03 Sep 2024 Direct F1, F4
transaction TRDA Common Stock Tax liability $73,169 -4,744 -1.4% $15.42 326,579 04 Sep 2024 Direct F1, F5
transaction TRDA Common Stock Tax liability $12,494 -826 -0.25% $15.13 325,753 05 Sep 2024 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.49 to $16.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.49 to $17.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $15.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.